Those Troublesome HCAHPS Scores

Cheryl ProvalThe only way to ace the HCAHPS is to go beyond caring for patients and make them believe you really do care for them. This journey is just beginning, and it is likely to turn up some interesting strategies along the way—not to mention a good deal of grumbling about the inherent unfairness of being judged on soft skills rather than science and outcomes. One thing is certain, though: The role of the HCAHPS in the government’s value-based purchasing program has the attention of every hospital executive in America. If you haven’t done so already, consider welcoming a new member to the C-suite, the chief patient experience officer, a term coined by Cleveland Clinic, which appointed the nation’s first CPEO. The lead story in this issue chronicles the luminary site’s path to turn around its scores, undertaken begrudgingly and paved with revelations. You also will hear how the then-new CEO of Advocate Good Samaritan Hospital, David Fox, lacking the budget to effect his will, put physicians at the center of a performance improvement initiative and earned a Malcolm Baldrige award for excellence. Finally, we offer a report from Dan Paoletti, CEO of the Ohio Health Information Partnership (OHIP), on what it takes to build a meaningful, statewide health information exchange.Cheryl Proval
Cheryl Proval,

Vice President, Executive Editor, Radiology Business

Cheryl began her career in journalism when Wite-Out was a relatively new technology. During the past 16 years, she has covered radiology and followed developments in healthcare policy. She holds a BA in History from the University of Delaware and likes nothing better than a good story, well told.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.